U.S. Senate Approves Measure to Support Operations at the FDA to Help Propel Bioscience & MedTech Investment and Innovation
Sponsored by CLSA, AB 602 Protects Patients with Diabetes from Counterfeit or Improperly Sold Diabetes Test Devices
As California’s legislature heads into its break for the summer, returning on Aug. 21, the top three bills of concern to the life sciences industry all face the potential for amendments before reaching their respective final floor votes.
Update on Key CLSA Federal Policy Activities in Washington, D.C.
The City of South San Francisco continues its economic and population growth at a rapid pace. Construction sites are numerous and further development plans are under consideration.
CLSA Member Boehringer Ingelheim expansion will bring nearly 300 new high-wage and highly-skilled positions to the City of Fremont.
On July 13, Medicare Trustees released their annual report predicting that, due to slower than expected growth in Medicare spending, the Independent Payment Advisory Board (IPAB) will not be triggered until 2021.
On July 14, 2017, CLSA partnered with Organovo, Takeda and Sanford Burnham Prebys to host a tour for members of the California Legislative Technology and Innovation Caucus.
CLSA’s Brett Johnson provides analysis to the San Francisco Business Times on three major bills (SB 790, SB 17 and AB 215) the life sciences sector is facing in Sacramento.
California policymakers are considering legislation (SB 790) that would restrict the California life sciences sector’s ability to provide continuing education to physicians and discuss the clinical benefits of medicines.